Trial · NCT07020104
The Role of Skin Sodium Accumulation in Chronic Kidney Disease
NCT07020104, Not applicable, Recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Role of Skin Sodium Accumulation in Chronic Kidney Disease. Trials, record NCT07020104. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07020104
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Role of Skin Sodium Accumulation in Chronic Kidney Disease
- NCT number
- NCT07020104
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Conditions
- Chronic Kidney Diseases
- Interventions
- Hydrochlorothiazide, Spironolactone, Lercanidipine, High sodium dietary intake (>200mmol/l), Low sodium dietary intake (<50mmol/l), High water intake, Habitual water intake
- First posted
- 2025-06-13
- Last updated
- 2025-06-13
Source ClinicalTrials.gov
Registered outcomes40
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Skin sodium content at baseline (A) | 0 week | Skin sodium content will be measured using the 7T sodium MRI |
| Primary | Muscle sodium content at baseline (A) | 0 week | Muscle sodium content will be measured using the 7T sodium MRI |
| Primary | Change from baseline in tissue sodium content after low and high sodium diet (B) | 2 weeks | |
| Primary | Change in tissue sodium content after treatment with hydrochloorthiazide, spironolacton and lercanidipine (C) | 6 weeks | To study the effect of hydrochloorthiazide, spironolacton and lercanidipine on tissue sodium content, to compare the effect among the various antihypertensive agents and to assess the effect of blood pressure regulation, increased renal sodium excretion and aldosteron blockade on tissue sodium content. |
| Primary | Change from baseline in tissue sodium content after habitual and high water intake (D) | 4 weeks | To evaluate the effect of high and habitual water intake on tissue sodium content. |
| Primary | Change from baseline in transepidermal water loss after habitual and high water intake (D) | 4 weeks | To evaluate the effect of high and habitual water intake on transepidermal water loss. |
| Primary | Incidence of hyponatremia and hypervolemia (D) | 4 weeks | Safety of high water intake in CKD patients with eGFR between 15 and 30ml/min/1.73m2 |
| Secondary | Correlation between tissue sodium content and total vessel density (A) | 0 week | Correlation between tissue sodium content measured with 7T Na-MRI and total vessel density using Sidestream Dark Field imaging. |
| Secondary | Correlation between tissue sodium content and perfused vessel density (A) | 0 week | Correlation between tissue sodium content measured with 7T Na-MRI and perfused vessel density using Sidestream Dark Field imaging. |
| Secondary | Correlation between tissue sodium content and proportion of perfused vessels (A) | 0 week | Correlation between tissue sodium content measured with 7T Na-MRI and proportion of perfused vessels using Sidestream Dark Field imaging. |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07020104
GET https://conductscience.org/api/trials/v1/NCT07020104/registered?page=2